A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the ...

A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumor uptake, sustained tumor retention, and high contrast in preclinical models, making it a prime candidate for a ...

Since its approval in 2018 by the US Food and Drug Administration, peptide receptor radionuclide therapy (PRRT) has become a mainstay in the treatment of neuroendocrine tumors. Lutetium-177-DOTATATE, ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ORLANDO -- An ...

Transaxial slices of baseline positron emission tomography (PET) and fused PET/magnetic resonance imaging (MRI; left) demonstrate a somatostatin receptor-expressing meningioma in the left cavernous ...

Comparative analysis of stereotactic body radiotherapy (SBRT) vs. SBRT with bridge therapies for hepatocellular carcinoma patients awaiting liver transplantation: A multi-center study (2010-2020).

The IAEA has recently launched SAFRON for Radionuclide Therapy, an incident learning system to help medical facilities improve safety of patients and staff. The objective of this new learning system ...

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the first clinical site for the Phase 1/2 LuMIERE study of FAP-2286, its novel peptide-targeted radionuclide ...

DALLAS, March 26 – Mental stress can trigger a lack of blood flow to the heart and increase the risk of death in people with coronary artery disease, researchers report in today’s rapid access ...

A secondary analysis of the phase III VISION trial presented at this year's American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium found that adding androgen receptor pathway ...